These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 35482114

  • 1. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies.
    Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A.
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3910-3916. PubMed ID: 35482114
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [18F]PSMA-1007 PET/CT.
    Bauckneht M, D'Amico F, Albano D, Balma M, Cabrini C, Dondi F, Di Raimondo T, Liberini V, Sofia L, Peano S, Riondato M, Fornarini G, Laudicella R, Carmisciano L, Lopci E, Zanca R, Rodari M, Raffa S, Donegani MI, Dubois D, Peñuela L, Marini C, Bertagna F, Papaleo A, Morbelli S, Sambuceti G, Ponzano M, Signori A.
    J Nucl Med; 2024 Oct 01; 65(10):1577-1583. PubMed ID: 39237346
    [Abstract] [Full Text] [Related]

  • 4. Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer.
    Seifert R, Telli T, Opitz M, Barbato F, Berliner C, Nader M, Umutlu L, Stuschke M, Hadaschik B, Herrmann K, Fendler WP.
    J Nucl Med; 2023 May 01; 64(5):738-743. PubMed ID: 36460340
    [Abstract] [Full Text] [Related]

  • 5. Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer.
    Ferraro DA, Laudicella R, Zeimpekis K, Mebert I, Müller J, Maurer A, Grünig H, Donati O, Sapienza MT, Rueschoff JH, Rupp N, Eberli D, Burger IA.
    Eur J Nucl Med Mol Imaging; 2022 Apr 01; 49(5):1721-1730. PubMed ID: 34725726
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer.
    Mingels C, Bohn KP, Rominger A, Afshar-Oromieh A, Alberts I.
    Eur J Nucl Med Mol Imaging; 2022 Jun 01; 49(7):2436-2444. PubMed ID: 35067735
    [Abstract] [Full Text] [Related]

  • 7. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging.
    Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, Müller J.
    Eur J Nucl Med Mol Imaging; 2021 Dec 01; 48(13):4483-4494. PubMed ID: 34120201
    [Abstract] [Full Text] [Related]

  • 8. 68Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer.
    de Jong AC, Smits M, van Riet J, Fütterer JJ, Brabander T, Hamberg P, van Oort IM, de Wit R, Lolkema MP, Mehra N, Segbers M, van der Veldt AAM.
    J Nucl Med; 2020 Nov 01; 61(11):1607-1614. PubMed ID: 32169916
    [Abstract] [Full Text] [Related]

  • 9. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
    Witkowska-Patena E, Giżewska A, Dziuk M, Miśko J, Budzyńska A, Walęcka-Mazur A.
    Clin Nucl Med; 2019 Dec 01; 44(12):e629-e633. PubMed ID: 31689286
    [Abstract] [Full Text] [Related]

  • 10. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy.
    Rauscher I, Krönke M, König M, Gafita A, Maurer T, Horn T, Schiller K, Weber W, Eiber M.
    J Nucl Med; 2020 Jan 01; 61(1):51-57. PubMed ID: 31253741
    [Abstract] [Full Text] [Related]

  • 11. Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation.
    Arnfield EG, Thomas PA, Roberts MJ, Pelecanos AM, Ramsay SC, Lin CY, Latter MJ, Garcia PL, Pattison DA.
    Eur J Nucl Med Mol Imaging; 2021 Dec 01; 48(13):4495-4507. PubMed ID: 34136957
    [Abstract] [Full Text] [Related]

  • 12. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
    Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2018 Oct 01; 45(11):1873-1883. PubMed ID: 29766246
    [Abstract] [Full Text] [Related]

  • 13. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug 01; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 14. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard.
    Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E.
    J Nucl Med; 2020 Apr 01; 61(4):527-532. PubMed ID: 31562225
    [Abstract] [Full Text] [Related]

  • 15. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.
    Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, Ma S, Wu P, Yang F, Guo W, Yang X, Yuan J, Shi Y, Wang J, Qin W.
    Theranostics; 2021 Apr 01; 11(17):8396-8411. PubMed ID: 34373749
    [Abstract] [Full Text] [Related]

  • 16. Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, Pinto PA, Wood BJ, Dahut WL, Gulley JL, Madan RA, Choyke PL, Turkbey B.
    J Nucl Med; 2023 Mar 01; 64(3):395-401. PubMed ID: 36265908
    [Abstract] [Full Text] [Related]

  • 17. Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer.
    Kim J, Lee S, Kim D, Kim HJ, Oh KT, Kim SJ, Choi YD, Giesel FL, Kopka K, Hoepping A, Lee M, Yun M.
    Eur J Nucl Med Mol Imaging; 2024 May 01; 51(6):1763-1772. PubMed ID: 38200396
    [Abstract] [Full Text] [Related]

  • 18. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep 01; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
    Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2017 Jun 01; 44(6):941-949. PubMed ID: 28138747
    [Abstract] [Full Text] [Related]

  • 20. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?
    Chen MY, Franklin A, Yaxley J, Gianduzzo T, McBean R, Wong D, Tatkovic A, McEwan L, Walters J, Kua B.
    BJU Int; 2020 Sep 01; 126(3):396-401. PubMed ID: 32592330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.